 Cellectar Biosciences Inc NASDAQ: CLRB has received a peer-reviewed National Institutes of Health NIH Phase II Small Business Innovation Research SBIR grant of approximately 2 million from the National Cancer Institute NCI. The Company is currently conducting a pivotal study of iopofosine I-131 CLR 131 in Waldenstroms macroglobulinemia WM patients who have received at least two prior lines of therapy. 